[go: up one dir, main page]
More Web Proxy on the site http://driver.im/
Next Article in Journal
Characterization of Timed Changes in Hepatic Copper Concentrations, Methionine Metabolism, Gene Expression, and Global DNA Methylation in the Jackson Toxic Milk Mouse Model of Wilson Disease
Previous Article in Journal
Human Papillomavirus 16 E6 Contributes HIF-1α Induced Warburg Effect by Attenuating the VHL-HIF-1α Interaction
You seem to have javascript disabled. Please note that many of the page functionalities won't work as expected without javascript enabled.
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 15
Issue 5
10.3390/ijms15057987
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Endothelial Nitric Oxide Synthase (eNOS) 4b/a Gene Polymorphisms and Coronary Artery Disease: Evidence from a Meta-Analysis

by
Yujiao Yang
†,
Kang Du
†,
Zhengxia Liu
and
Xiang Lu
*
Department of Geriatrics, the Second Affiliated Hospital, Nanjing Medical University, Nanjing 210029, Jiangsu, China
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Int. J. Mol. Sci. 2014, 15(5), 7987-8003; https://doi.org/10.3390/ijms15057987
Submission received: 25 March 2014 / Revised: 24 April 2014 / Accepted: 29 April 2014 / Published: 7 May 2014
(This article belongs to the Section Molecular Pathology, Diagnostics, and Therapeutics)
Browse Figures

<p>Flow diagram of study identification.</p> ">
<p>Forest plot of CAD risk associated with the <span class="html-italic">eNOS 4b/a</span> polymorphism by source of control (homozygote comparison).</p> ">
<p>Begg’s funnel plot of publication bias test (homozygote comparison). (<b>a</b>) Before trim and fill method; and (<b>b</b>) After trim and fill method.</p> ">
Versions Notes

Abstract

:
A variety of studies have suggested that the 4b/a polymorphism in the endothelial nitric oxide synthase (eNOS) was associated with coronary artery disease (CAD) risk. However, the data remain conflicting. The aim of the present meta-analysis was to estimate the overall association between risk of CAD and eNOS 4b/a polymorphism. Case-control, cohort or cross-sectional studies evaluating the association between eNOS 4b/a polymorphism and CAD susceptibility were systematically identified in PubMed up to 31 October 2013. Pooled odds ratios (OR) and corresponding 95% confidence intervals (CIs) were calculated to assess the association in overall and subgroup analyses. A total of 10,617 cases and 8302 controls from 37 studies were included in the study. The results of overall analysis revealed significant positive associations between CAD risk and eNOS 4b/a polymorphism in homozygote comparisons (OR = 1.47, 95% CI = 1.16–1.87), heterozygote comparisons (OR = 1.14, 95% CI = 1.02–1.27) and dominant models (OR = 1.18, 95% CI = 1.06–1.33). In subgroup analyses, similar associations were identified in African individuals, as determined using population-based source subgroups and noted in small-and-moderate sample size subgroups (case sample size or control sample size <500). The current meta-analysis revealed that eNOS 4b/a polymorphisms could be a risk factor for developing CAD, particularly in African populations and population-based subgroups.

1. Introduction

Coronary artery disease (CAD) also known as coronary heart disease (CHD), is the leading cause of death and disability worldwide [1,2]. CAD is associated with genetic and environmental factors, as well as their interactions [3]. Confirmed risk factors for CAD include hypercholesterolemia, hypertension, smoking, and diabetes [4]. However, in addition to modifiable risk factors, genetic factors can also predispose individuals to CAD. It has been estimated that genetic risk factors explain approximately 20%–60% of CAD cases [5].
Nitric oxide (NO) is an important atheroprotective mediator that helps mediate endothelium-dependent vasodilatation. Abnormalities in NO generation could play an important role in the pathophysiology of CAD [6]. NO is synthesized from l-arginine by the action of nitric oxide synthase (NOS). There are at least three isoenzymes of NOS: inducible NOS, neuronal NOS, and endothelial NOS (eNOS) [7]. The eNOS gene is located on chromosome 7q35–q36 and is sized 21 kilobases (kb) [8]. A number of studies have suggested that polymorphisms in the eNOS gene affected NO availability and were associated with CAD morbidity. One of the most clinically relevant eNOS variants forms 27-basepair (bp) tandem repeats in intron 4 (4b/a). The eNOS 4b allele contains five repeats of the 27 bp sequence, whereas eNOS 4a, which is the rare allele, carries a deletion of one of the first three of these repeats [9].
The association between eNOS 4b/a gene polymorphisms and CAD remains controversial, and the results of two previous meta-analyses were inconsistent [10,11]. In 2004, Casas et al. performed a meta-analysis of 16 studies and found an increased risk of ischemic heart disease (IHD) in individuals carrying the homozygous a allele compared with the b allele [10]. However, a subsequent meta-analysis in 2010 reported conflicting data, where eNOS 4b/a did not significantly increase the risk of developing CAD [11]. A large number of new case-control studies assessing the association between eNOS 4b/a polymorphisms and the CAD risk have been published since 2010. Therefore, we performed a meta-analysis using a more complete database to clarify the association between eNOS 4b/a polymorphisms and CAD risk.

2. Results and Discussion

2.1. Characteristics of Included Studies

A total of 373 papers were initially identified during the literature search and from other sources; 37 of these met the inclusion criteria for this analysis [9,12–47]. A flow chart describing the literature search and study identification is shown in Figure 1. The meta-analysis of the 4b/a polymorphism included 10,617 CAD cases and 8302 controls. The study characteristics are summarized in Table 1. The number of subjects in the studies varied considerably (range from 40 to 1265 in the case group and from 34 to 620 in the control group). Among the 37 case-control studies, 11 studies included Asian population [15–25], and 26 assessed non-Asians [9,12–14,26–47]. Controls were mainly matched in terms of gender and age. Fourteen studies were hospital-based [16–18,20,21,25,28,37–40,42,43,45], and 20 were population-based [9,12–15,19,22,23,26,27,29–34,36,41,46,47]. Thirty studies were performed using <500 subjects in the case group [12–27,29,33–36,38–47] and 33 were conducted with <500 subjects in the control group [9,12–15,17–29,32,34–47]. Furthermore, there were 20 studies of CAD [9,18,20,22,23,25,29,30,32,34–40,42–44,46], four of CHD [17,26–28], three of acute myocardial infarction [15,19,45], six of myocardial infarction (MI) [12–14,16,31,41], and four of acute coronary syndrome [21,24,33,47].

2.2. Meta-Analysis Results

The relationship between eNOS 4b/a polymorphisms and CAD risk are summarized in Table 2. Overall, significant positive associations between CAD risk and eNOS 4b/a polymorphism were identified in the homozygote comparison (aa vs. bb, OR = 1.47, 95% CI = 1.16–1.87, pheterogeneity = 0.085), the heterozygote comparison (ab vs. bb, OR = 1.14, 95% CI = 1.02–1.27, pheterogeneity < 0.001) and the dominant model (ab + aa vs. bb, OR = 1.18, 95% CI = 1.06–1.33, pheterogeneity < 0.001).
In a stratified analysis by the source of the control population, significantly increased CAD risk was detected in the population-based subgroup of all the three genetic models (OR = 1.64, 95% CI = 1.18–2.27, p = 0.070 for the homozygote comparison; OR = 1.16, 95% CI = 1.00–1.35, p < 0.001 for the heterozygote comparison; and OR = 1.21, 95% CI = 1.05–1.40, p < 0.001 for the dominant model). There was no significantly increased CAD risk in the hospital-based subgroup (OR = 1.11, 95% CI =0.78–1.56, p = 0.509 for the homozygote comparison; OR = 1.04, 95% CI = 0.88–1.23, p = 0.072 for the heterozygote comparison; and OR = 1.07, 95% CI = 0.89–1.27, p = 0.027 in the dominant model) (Figure 2).
The data were also stratified into Asian and non-Asian subpopulations. There was a statistically significant association in the non-Asian subgroup in the homozygote comparison (OR = 1.41, 95% CI = 1.08–1.84, p = 0.080) and the dominant model (OR = 1.16, 95% CI = 1.02–1.32, p < 0.001). Non-Asians were then further stratified into Caucasians, Africans, and others. The populations of an American study and a Brazilian study were both composed of two ethnicities: Caucasians and Africans [39,40]. The different ethnic descents in these studies were considered to be two independent studies during sub-stratified analyses. Statistically significant associations were noted in African populations in three genetic models (homozygote comparison OR = 2.93, 95% CI = 1.71–5.03, p = 0.821; heterozygote comparison OR = 1.46, 95% CI = 1.16–1.83, p = 0.353; and the dominant model OR = 1.58, 95% CI = 1.27–1.96, p = 0.370). Interestingly, significant associations were also found in Asian (OR = 1.82, 95% CI = 1.03–3.20, p = 0.316) and “other” (OR = 2.65, 95% CI = 1.37–5.13, p = 0.369) populations during the homozygote comparison. In contrast, no statistically significant associations were identified in Caucasian populations (OR = 1.03, 95% CI = 0.80–1.31, p = 0.621 in the homozygote comparison; OR = 1.04, 95% CI = 0.90–1.20, p = 0.006 in the heterozygote comparison; OR = 1.04, 95% CI = 0.91–1.19, p = 0.007 in the dominant model) (Supplementary Figure S1).
The data were then also stratified according to case sample size into large (>500 total cases) and small-and-moderate case sample (<500 total cases) subgroups. Significant associations between eNOS 4b/a polymorphisms and CAD risk were observed in the small-and-moderate case sample subgroup (OR = 1.75, 95% CI = 1.35–2.28, p = 0.262 in the homozygote comparison; OR = 1.20, 95% CI = 1.07–1.35, p = 0.011 in the heterozygote comparison; and OR = 1.26, 95% CI = 1.11–1.42, p = 0.002 in the dominant model) but not in the large case sample subgroup. The data were then stratified into large control (>500 control individuals) and small-and-moderate control sample (<500 control individuals) subgroups. Similar to the data from the case sample size analyses, significant associations were observed in the small-and-moderate control sample subgroup (OR = 1.56, 95% CI = 1.19–2.05, p = 0.113 for the homozygote comparison; OR = 1.15, 95% CI = 1.01–1.31, p < 0.001 for the heterozygote comparison; and OR = 1.20, 95% CI = 1.06–1.36, p < 0.001 in the dominant model), but not the large case sample subgroup.
Finally, a subgroup analysis for MI was performed. There were significant associations between eNOS 4b/a polymorphisms and CAD risk with the homozygote comparison (OR = 2.30, 95% CI = 1.17–4.51, p = 0.020), heterozygote comparison (OR = 1.42, 95% CI = 1.07–1.89, p = 0.002), and dominant model (OR = 1.50, 95% CI = 1.09–2.07, p < 0.001) in patients with MI.

2.3. Evaluation of Heterogeneity

There was minor heterogeneity among studies in the recessive model (ab + bb vs. aa, pheterogeneity = 0.213, I2 = 15.4%), while the results of heterogeneity tests were significant in the other three genetic models (aa vs. bb, pheterogeneity = 0.085, I2 = 25.5%; ab vs bb, pheterogeneity < 0.001, I2 = 56.7%; ab + aa vs. bb, pheterogeneity < 0.001, I2 = 61.1%). The random-effects models were used in all the four genetic models. Meta-regression analyses were then performed to evaluate the extent to which different variables explained the heterogeneity. The results revealed that the heterogeneity could be explained by case sample size (p = 0.015) and total sample size (p = 0.015) in the homozygote comparison. However, population ethnicity, year of publication, source of control population, total sample size, and outcome were not statistically correlated with heterogeneity (p > 0.05).

2.4. Sensitivity Analysis and Publication Bias

Sensitivity analysis was performed by omitting one study at a time. No significant differences in the data were observed, indicating that the results were statistically reliable (Supplementary Figure S2). The publication bias of the studies was assessed by performing the Begg’s funnel plot and Egger’s test. There was no obvious publication bias in the heterozygote comparison (ab vs. bb, Begg’s test p = 0.754, Egger’s test p = 0.473), and the dominant model (ab + aa vs. bb, Begg’s test p = 0.619, Egger’s test p = 0.274). The shape of the funnel plot for the homozygote comparison appeared to be approximately asymmetrical, which was confirmed by the test results (aa vs. bb, Begg’s test p = 0.022, Egger’s test p = 0.004). However, adjusting the model by the trim and fill method did not influence the conclusions (OR = 1.23, 95% CI = 1.02–1.48) (Figure 3).

2.5. Discussion

The meta-analysis revealed that eNOS 4b/a polymorphisms were significantly associated with CAD in three genetic models (dominant model, homozygote comparison, and heterozygote comparison). These data suggest that carriers of the a allele of the eNOS 4b/a gene might be predisposed to CAD. Heterogeneity was observed in these three models; however, subsequent meta-regression analyses revealed that case and total sample size could explain the heterogeneity. Subgroup analysis based on source of the control population revealed that population-based subgroups with the aa or ab genotypes had a significantly increased risk of CAD. In stratified analyses according to ethnicity, significantly increased risk was detected in the African subgroup with the aa or ab genotypes and the Asian subgroup with the aa genotype. Positive associations were also identified in studies whose case or control sample size was <500 with the aa or ab genotypes. Similarly, significant associations were identified in studies with the aa or ab genotypes in a subgroup analysis according to MI.
In 1998, a Japanese study including 413 subjects reported that the plasma levels of mono-nitrogen oxides in the a allele group (31.2 ± 2.00 μmol/L) were significantly lower than in the b allele group (35.5 ± 0.93 μmol/L) [48]. Reduced plasma concentrations of nitrogen oxides (NO) in carriers of the a allele were also identified in a study by Rittig et al. in a German population [49]. Prevailing experimental and clinical data suggest that decreased NO bioavailability accelerates the progression of atherosclerosis presumably through mechanisms such as platelet activation, vascular smooth muscle proliferation, leukocyte adhesion to the endothelium and increased vascular production of reactive oxygen species [50,51]. Therefore, it is possible that eNOS 4b/a gene polymorphisms could contribute to CAD risk by decreasing NO production, which subsequently affects the development of CAD. However, because this variant is located in the intronic region, it is possible that it is in linkage disequilibrium with other functional variants in regulatory regions of the NOS gene. In 2002, Wang et al. demonstrated that the eNOS 4a allele coordinated with the T-786C variant in the promoter region to regulate the transcriptional efficiency of eNOS in a haplotype-specific fashion [52]. In 2013, Narne et al. reported that the eNOS 4b/a polymorphism affected the bioavailability and activity of NO via linkage disequilibrium with T-786C and G894T variants [25]. Consistent with these observations, our meta-analysis revealed that individuals carrying the eNOS 4a allele had a higher CAD risk than subjects carrying the 4b allele.
Our results also suggested that the 4a allele might be a risk factor for CAD among population-based but not hospital-based subgroups. One explanation for this is that there were differences in the frequency of exposure to risk factors between hospital- and population-based studies. The use of hospital-based population might limit the general applicability of the data. Furthermore, the sample size and number of studies in the hospital-based group might not be sufficient to evaluate potential associations.
In the subgroup analysis according to ethnicity, an increased risk in 4a carriers was identified among African and Asian populations but not Caucasians. The results could be explained by varying susceptibility of different ethnicities to the eNOS 4b/a polymorphism among different ethnicities. Environmental characteristics might also contribute to this discrepancy.
Two previous meta-analyses assessing eNOS 4b/a and CAD risk have been performed. In 2004, one study reported an association between eNOS 4a/a and ischemic heart disease compared with eNOS 4b/b [10]. Although IHD and CAD have overlapping pathogeneses, they are different disease. A second meta-analysis performed in 2010 did not reveal any association between this eNOS genetic variant and CAD risk [11]; therefore, our results contradict this study. This could be explained by several reasons. First, different inclusion and exclusion criteria were used. We excluded four studies in which the control population deviated from Hardy-Weinberg equilibrium (HWE) [53–56]. We also incorporated novel data published between 2010 and October 2013 in our study. Therefore, the number and content of the studies included by Li et al. and in the current meta-analysis differed. Second, we performed overall analyses in four genetic models; in contrast Li et al. did not perform homozygote comparison and heterozygote comparisons. We also performed subgroup analysis based on ethnicity, the source of the control population, and case sample size to identify all possible associations between 4b/a polymorphisms and CAD; these factors were not investigated previously.
The present study has some limitations. First, heterogeneity was detected in three genetic models, suggesting that results should be interpreted with caution. Second, most of the included studies were case-control studies, where the cases were survivors of cardiovascular events; those who did not survive were not enrolled. Finally, the sample size in the studies was inadequate. The insufficient sample size might increase the probability of false positives or false negatives.

3. Experimental Section

3.1. Literature Search

We systematically searched PubMed using the following medical subject headings (MeSH) or search terms: (“CHD” OR “atherosclerosis” OR “coronary atherosclerosis” OR “aortic atherosclerosis” OR “coronary heart disease” OR “coronary artery disease” OR “coronary disease” OR “myocardial infarction” OR “MI” OR “acute coronary syndrome”) and (“polymorphism*” OR “variation”) and (“eNOS” OR “endothelial nitric oxide synthase”). The search covered all English language publications within a range of published years from 1996 to 2013 (the last search was performed on 31 October 2013). The bibliographies of previous meta-analyses and published reviews were also checked for additional relevant publications.

3.2. Inclusion and Exclusion Criteria

The inclusion criteria for studies were as follows: (1) independent case-control, cohort or cross-sectional studies; (2) studies that evaluated the association between eNOS intron 4b/a variable number of tandem repeats (VNTR) polymorphisms and CAD susceptibility; (3) studies that provided complete data regarding genotype number and allele frequencies; (4) studies in which CAD was diagnosed based on coronary angiography as well as clinical criteria with clearly reported details; (5) studies that also included controls demonstrated to lack CAD either by coronary arteriography or by clinical criteria; and (6) studies that were published in English. The exclusion criteria were as follows: (1) insufficient data regarding genotypes and allele frequencies; (2) unconfirmed diagnosis of CAD; (3) the genotype distribution of the control population did not conform to HWE; and (4) overlapping publications.

3.3. Data Extraction

Two researchers (Y.Y. and K.D.) extracted information including the first author, year of publication, country, ethnicity of the study population, source of controls, genotype number in cases and controls, HWE in controls and study outcome. Data were extracted separately and compared to reach a consensus. Different ethnicities were categorized as Asians and non-Asians (Caucasians, Africans, or others). Different ethnic descents in one study were considered to be independent studies when subanalyses based on ethnicity were performed.

3.4. Statistical Analysis

The association between eNOS 4b/a gene polymorphisms and CAD was compared using the odds ratio (OR) corresponding to a 95% confidence interval (95% CI). We used four different genetic models in our analysis: homozygote comparison (aa vs. bb), heterozygote comparison (ab vs. bb), dominant (aa + ab vs. bb), and recessive models (aa vs. ab + bb).
Heterogeneity between studies was assessed using p values for the Q statistic and I2 values. Significance was set at the p < 0.1 level; p < 0.1 for the Q test indicated there was heterogeneity across the studies and p > 0.1 for the Q test indicated a lack of heterogeneity among studies. The random-effects model was used to estimate the pooled OR according to the DerSimonian and Laird method [57]. I2 was calculated to describe the percentage of variation caused by the heterogeneity: 0%–25%, no heterogeneity; 25%–50%, moderate heterogeneity; 50%–75%, large heterogeneity; and 75%–100%, extreme heterogeneity).
To determine the source of heterogeneity across studies, logistic meta-regression analyses were performed. Publication year, population ethnicity, source of the control group, outcome, total sample size, case sample size, control sample size, and the ratio of case size to control size were examined to evaluate the extent to which different variables explained any observed heterogeneity. Stratified analyses were also performed for ethnicity, source of controls, and case sample size. Sensitivity analyses were conducted by removing each study individually and consecutively from the combined data set. Re-analysis of the remaining studies, allowed the robustness of the main findings to be tested. In addition, a funnel plot was used to estimate the potential publication bias; Begg’s and Egger’s tests were then used to examine funnel plot asymmetry with significance set at p < 0.05, and the trim and fill method was performed when bias was detected. STATA 12.0 software was used to perform all statistical analyses (StataCorp, College Station, TX, USA).

4. Conclusions

In conclusion, the results of the current meta-analysis suggested that eNOS 4b/a polymorphisms could increase the risk of CAD, particularly in African populations and among the population-based studies. Further studies with larger sample sizes should be performed to confirm these findings.

Supplementary Information

ijms-15-07987-s001.pdf

Acknowledgments

Grants from the Natural Science Foundation of China (No.81270428) supported this study.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Gouvinhas, C.; Severo, M.; Azevedo, A.; Lunet, N. Worldwide patterns of ischemic heart disease mortality from 1980 to 2010. Int. J. Cardiol 2013, 170, 309–314. [Google Scholar]
  2. Salomon, J.A.; Vos, T.; Hogan, D.R.; Gagnon, M.; Naghavi, M.; Mokdad, A.; Begum, N.; Shah, R.; Karyana, M.; Kosen, S.; et al. Common values in assessing health outcomes from disease and injury: Disability weights measurement study for the global burden of disease study 2010. Lancet 2012, 380, 2129–2143. [Google Scholar]
  3. Prins, B.P.; Lagou, V.; Asselbergs, F.W.; Snieder, H.; Fu, J. Genetics of coronary artery disease: Genome- wide association studies and beyond. Atherosclerosis 2012, 225, 1–10. [Google Scholar]
  4. Smith, F.B.; Lee, A.J.; Fowkes, F.G.; Price, J.F.; Rumley, A.; Lowe, G.D. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh artery study. Arterioscler. Thromb. Vasc. Biol 1997, 17, 3321–3325. [Google Scholar]
  5. Kraus, W.E. Genetic approaches for the investigation of genes associated with coronary heart disease. Am. Heart J 2000, 140, S27–S35. [Google Scholar]
  6. Kugiyama, K.; Yasue, H.; Okumura, K.; Ogawa, H.; Fujimoto, K.; Nakao, K.; Yoshimura, M.; Motoyama, T.; Inobe, Y.; Kawano, H. Nitric oxide activity is deficient in spasm arteries of patients with coronary spastic angina. Circulation 1996, 94, 266–271. [Google Scholar]
  7. Nathan, C.; Xie, Q.W. Nitric oxide synthases: Roles, tolls, and controls. Cell 1994, 78, 915–918. [Google Scholar]
  8. Marsden, P.A.; Heng, H.H.; Scherer, S.W.; Stewart, R.J.; Hall, A.V.; Shi, X.M.; Tsui, L.C.; Schappert, K.T. Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene. J. Biol. Chem 1993, 268, 17478–17488. [Google Scholar]
  9. Wang, X.L.; Sim, A.S.; Badenhop, R.F.; McCredie, R.M.; Wilcken, D.E. A smoking- dependent risk of coronary artery disease associated with a polymorphism of the endothelial nitric oxide synthase gene. Nat. Med 1996, 2, 41–45. [Google Scholar]
  10. Casas, J.P.; Bautista, L.E.; Humphries, S.E.; Hingorani, A.D. Endothelial nitric oxide synthase genotype and ischemic heart disease: Meta-analysis of 26 studies involving 23028 subjects. Circulation 2004, 109, 1359–1365. [Google Scholar]
  11. Li, J.; Wu, X.; Li, X.; Feng, G.; He, L.; Shi, Y. The endothelial nitric oxide synthase gene is associated with coronary artery disease: A meta-analysis. Cardiology 2010, 116, 271–278. [Google Scholar]
  12. Hooper, W.C.; Lally, C.; Austin, H.; Benson, J.; Dilley, A.; Wenger, N.K.; Whitsett, C.; Rawlins, P.; Evatt, B.L. The relationship between polymorphisms in the endothelial cell nitric oxide synthase gene and the platelet gpiiia gene with myocardial infarction and venous thromboembolism in African Americans. Chest 1999, 116, 880–886. [Google Scholar]
  13. Kallel, A.; Sbai, M.H.; Sediri, Y.; Abdessalem, S.; Mourali, M.S.; Feki, M.; Mechmeche, R.; Jemaa, R.; Kaabachi, N. Polymorphisms of the NOS3 gene and risk of myocardial infarction in the Tunisian population. Cytokine 2013, 64, 646–651. [Google Scholar]
  14. Jemaa, R.; Kallel, A.; Sediri, Y.; Abdessalem, S.; Mourali, M.S.; Feki, M.; Mechmeche, R.; Kaabachi, N. Association between endothelial nitric oxide gene intron 4a 4b VNTR polymorphism and plasma homocysteine concentrations in Tunisian male patients with myocardial infarction. Nutr. Res 2012, 32, 342–346. [Google Scholar]
  15. Hibi, K.; Ishigami, T.; Tamura, K.; Mizushima, S.; Nyui, N.; Fujita, T.; Ochiai, H.; Kosuge, M.; Watanabe, Y.; Yoshii, Y.; et al. Endothelial nitric oxide synthase gene polymorphism and acute myocardial infarction. Hypertension 1998, 32, 521–526. [Google Scholar]
  16. Ichihara, S.; Yamada, Y.; Fujimura, T.; Nakashima, N.; Yokota, M. Association of a polymorphism of the endothelial constitutive nitric oxide synthase gene with myocardial infarction in the Japanese population. Am. J. Cardiol 1998, 81, 83–86. [Google Scholar]
  17. Odawara, M.; Sasaki, K.; Tachi, Y.; Yamashita, K. Endothelial nitric oxide synthase gene polymorphism and coronary heart disease in Japanese NIDDM. Diabetologia 1998, 41, 365–366. [Google Scholar]
  18. Nakagami, H.; Ikeda, U.; Maeda, Y.; Yamamoto, K.; Hojo, Y.; Kario, K.; Kuroki, S.; Shimada, K. Coronary artery disease and endothelial nitric oxide synthase and angiotensin-converting enzyme gene polymorphisms. J. Thromb. Thrombolysis 1999, 8, 191–195. [Google Scholar]
  19. Park, J.E.; Lee, W.H.; Hwang, T.H.; Chu, J.A.; Kim, S.; Choi, Y.H.; Kim, J.S.; Kim, D.K.; Lee, S.H.; Hong, K.P.; et al. Aging affects the association between endothelial nitric oxide synthase gene polymorphism and acute myocardial infarction in the Korean male population. Korean J. Intern. Med 2000, 15, 65–70. [Google Scholar]
  20. Hwang, J.J.; Tsai, C.T.; Yeh, H.M.; Chiang, F.T.; Hsu, K.L.; Tseng, C.D.; Liau, C.S.; Tseng, Y.Z.; Lai, L.P. The 27-bp tandem repeat polymorphism in intron 4 of the endothelial nitric oxide synthase gene is not associated with coronary artery disease in a hospital-based Taiwanese population. Cardiology 2002, 97, 67–72. [Google Scholar]
  21. Park, K.W.; You, K.H.; Oh, S.; Chae, I.H.; Kim, H.S.; Oh, B.H.; Lee, M.M.; Park, Y.B. Association of endothelial constitutive nitric oxide synthase gene polymorphism with acute coronary syndrome in Koreans. Heart 2004, 90, 282–285. [Google Scholar]
  22. Kim, I.J.; Bae, J.; Lim, S.W.; Cha, D.H.; Cho, H.J.; Kim, S.; Yang, D.H.; Hwang, S.G.; Oh, D.; Kim, N.K. Influence of endothelial nitric oxide synthase gene polymorphisms (-786T>C, 4a4b, 894G>T) in Korean patients with coronary artery disease. Thromb. Res 2007, 119, 579–585. [Google Scholar]
  23. Bae, J.; Kim, I.J.; Hong, S.H.; Sung, J.H.; Lim, S.W.; Cha, D.H.; Cho, Y.W.; Oh, D.; Kim, N.K. Association of endothelial nitric oxide synthase polymorphisms with coronary artery disease in Korean individuals with or without diabetes mellitus. Exp. Ther. Med 2010, 1, 719–724. [Google Scholar]
  24. Gururajan, P.; Gurumurthy, P.; Victor, D.; Rao, G.S.N.; Babu, R.S.; Bharati, A.S.; Cherian, K.M. Plasma total nitric oxide and endothelial constitutive nitric oxide synthase (ecNOS) gene polymorphism: A study in a South Indian population. Biochem. Genet 2011, 49, 96–103. [Google Scholar]
  25. Narne, P.; Ponnaluri, K.C.; Singh, S.; Siraj, M.; Ishaq, M. Association of the genetic variants of endothelial nitric oxide synthase gene with angiographically defined coronary artery disease and myocardial infarction in south Indian patients with type 2 diabetes mellitus. J. Diabetes Complicat 2013, 27, 255–261. [Google Scholar]
  26. Fowkes, F.G.; Lee, A.J.; Hau, C.M.; Cooke, A.; Connor, J.M.; Lowe, G.D. Methylene tetrahydrofolate reductase (MTHFR) and nitric oxide synthase (ecNOS) genes and risks of peripheral arterial disease and coronary heart disease: Edinburgh artery study. Atherosclerosis 2000, 150, 179–185. [Google Scholar]
  27. Pulkkinen, A.; Viitanen, L.; Kareinen, A.; Lehto, S.; Vauhkonen, I.; Laakso, M. Intron 4 polymorphism of the endothelial nitric oxide synthase gene is associated with elevated blood pressure in type 2 diabetic patients with coronary heart disease. J. Mol. Med 2000, 78, 372–379. [Google Scholar]
  28. Sigusch, H.H.; Surber, R.; Lehmann, M.H.; Surber, S.; Weber, J.; Henke, A.; Reinhardt, D.; Hoffmann, A.; Figulla, H.R. Lack of association between 27-bp repeat polymorphism in intron 4 of the endothelial nitric oxide synthase gene and the risk of coronary artery disease. Scand. J. Clin. Lab. Investig 2000, 60, 229–235. [Google Scholar]
  29. Alvarez, R.; Gonzalez, P.; Batalla, A.; Reguero, J.R.; Iglesias-Cubero, G.; Hevia, S.; Cortina, A.; Merino, E.; Gonzalez, I.; Alvarez, V.; et al. Association between the NOS3 (−786 T/C) and the ACE (I/D) DNA genotypes and early coronary artery disease. Nitric Oxide 2001, 5, 343–348. [Google Scholar]
  30. Granath, B.; Taylor, R.R.; van Bockxmeer, F.M.; Mamotte, C.D. Lack of evidence for association between endothelial nitric oxide synthase gene polymorphisms and coronary artery disease in the Australian Caucasian population. Eur. J. Prev. Cardiol 2001, 8, 235–241. [Google Scholar]
  31. Gardemann, A.; Lohre, J.; Cayci, S.; Katz, N.; Tillmanns, H.; Haberbosch, W. The T allele of the missense Glu298Asp endothelial nitric oxide synthase gene polymorphism is associated with coronary heart disease in younger individuals with high atherosclerotic risk profile. Atherosclerosis 2002, 160, 167–175. [Google Scholar]
  32. Agema, W.R.; de Maat, M.P.; Zwinderman, A.H.; Kastelein, J.J.; Rabelink, T.J.; van Boven, A.J.; Feskens, E.J.; Boer, J.M.; van der Wall, E.E.; Jukema, J.W. An integrated evaluation of endothelial constitutive nitric oxide synthase polymorphisms and coronary artery disease in men. Clin. Sci 2004, 107, 255–261. [Google Scholar]
  33. Fatini, C.; Sofi, F.; Sticchi, E.; Gensini, F.; Gori, A.M.; Fedi, S.; Lapini, I.; Rostagno, C.; Comeglio, M.; Brogi, D.; et al. Influence of endothelial nitric oxide synthase gene polymorphisms (G894T, 4a4b, T-786C) and hyperhomocysteinemia on the predisposition to acute coronary syndromes. Am. Heart J 2004, 147, 516–521. [Google Scholar]
  34. Letonja, M. The eNOS gene polymorphism does not have a major impact on lipid parameters and premature coronary artery disease in Caucasian women. Acta Cardiol 2004, 59, 618–622. [Google Scholar]
  35. Milutinovic, A.; Hruskovicova, H. The eNOS gene polymorphism does not have a major impact on lipid parameters and premature coronary artery disease in Slovene men (Caucasians). Folia Biol 2005, 51, 47–49. [Google Scholar]
  36. Vasilakou, M.; Votteas, V.; Kasparian, C.; Pantazopoulos, N.; Dedoussis, G.; Deltas, C.; Nastos, P.; Nikolakis, D.; Lamnissou, K. Lack of association between endothelial nitric oxide synthase gene polymorphisms and risk of premature coronary artery disease in the Greek population. Acta Cardiol 2008, 63, 609–614. [Google Scholar]
  37. Kincl, V.; Vasku, A.; Meluzin, J.; Panovsky, R.; Semenka, J.; Groch, L. Association of the eNOS 4a/b and -786T/C polymormphisms with coronary artery disease, obesity and diabetes mellitus. Folia Biol 2009, 55, 187–191. [Google Scholar]
  38. Meluzin, J.; Vasku, A.; Kincl, V.; Panovsky, R.; Sramkova, T. Association of coronary artery disease, erectile dysfunction, and endothelial nitric oxide synthase polymorphisms. Heart Vessels 2009, 24, 157–163. [Google Scholar]
  39. Rao, S.; Austin, H.; Davidoff, M.N.; Zafari, A.M. Endothelial nitric oxide synthase intron 4 polymorphism is a marker for coronary artery disease in African-American and Caucasian men. Ethn. Dis 2005, 15, 191–197. [Google Scholar]
  40. Rios, D.L.; D’Onofrio, L.O.; Souza, J.K.; Queiroz, A.M.; Raduy-Maron, L.; Silva-Neto, N.; Carvalho, H.G.; Santos-Filho, A.; Galvao-Castro, B. Smoking-dependent and haplotype-specific effects of endothelial nitric oxide synthase gene polymorphisms on angiographically assessed coronary artery disease in Caucasian- And african-Brazilians. Atherosclerosis 2007, 193, 135–141. [Google Scholar]
  41. Cine, N.; Hatemi, A.C.; Erginel-Unaltuna, N. Association of a polymorphism of the ecNOS gene with myocardial infarction in a subgroup of Turkish MI patients. Clin. Genet 2002, 61, 66–70. [Google Scholar]
  42. Matyar, S.; Attila, G.; Acarturk, E.; Akpinar, O.; Inal, T. eNOS gene intron 4 a/b VNTR polymorphism is a risk factor for coronary artery disease in Southern Turkey. Clin. Chim. Acta 2005, 354, 153–158. [Google Scholar]
  43. Agirbasli, D.; Agirbasli, M.; Williams, S.M.; Phillips, J.A., III. Interaction among 5,10 methylenetetrahydrofolate reductase, plasminogen activator inhibitor and endothelial nitric oxide synthase gene polymorphisms predicts the severity of coronary artery disease in Turkish patients. Coron. Artery Dis 2006, 17, 413–417. [Google Scholar]
  44. Salimi, S.; Firoozrai, M.; Nourmohammadi, I.; Shabani, M.; Mohebbi, A. Endothelial nitric oxide synthase gene intron4 VNTR polymorphism in patients with coronary artery disease in Iran. Indian J. Med. Res 2006, 124, 683–688. [Google Scholar]
  45. Sampaio, M.F.; Hirata, M.H.; Hirata, R.D.; Santos, F.C.; Picciotti, R.; Luchessi, A.D.; de Quateli Doi, S.; Armaganijan, D.; Batlouni, M. AMI is associated with polymorphisms in the NOS3 and FGB but not in PAI-1 genes in young adults. Clin. Chim. Acta 2007, 377, 154–162. [Google Scholar]
  46. Jaramillo, P.C.; Lanas, C.; Lanas, F.; Salazar, L.A. Polymorphisms of the NOS3 gene in Southern Chilean subjects with coronary artery disease and controls. Clin. Chim. Acta 2010, 411, 258–262. [Google Scholar]
  47. Da Costa, Escobar; Piccoli, J.; Manfredini, V.; Hamester, F.I.; Bandinelli, J.B.; Turkienicz, I.M.; Chies, J.A.; Peres, A.; Bodanese, L.C.; Bogo, M.R. Interaction between endothelial nitric oxide synthase gene polymorphisms (-786T>C, 894G>T and intron 4 a/b) and cardiovascular risk factors in acute coronary syndromes. Arch. Med. Res 2012, 43, 205–211. [Google Scholar]
  48. Tsukada, T.; Yokoyama, K.; Arai, T.; Takemoto, F.; Hara, S.; Yamada, A.; Kawaguchi, Y.; Hosoya, T.; Igari, J. Evidence of association of the ecNOS gene polymorphism with plasma no metabolite levels in humans. Biochem. Biophys. Res. Commun 1998, 245, 190–193. [Google Scholar]
  49. Rittig, K.; Holder, K.; Stock, J.; Tschritter, O.; Peter, A.; Stefan, N.; Fritsche, A.; Machicao, F.; Haring, H.U.; Balletshofer, B. Endothelial no-synthase intron 4 polymorphism is associated with disturbed in vivo nitric oxide production in individuals prone to type 2 diabetes. Horm. Metab. Res 2008, 40, 13–17. [Google Scholar]
  50. Kojda, G.; Harrison, D. Interactions between no and reactive oxygen species: Pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovasc. Res 1999, 43, 562–571. [Google Scholar]
  51. Skovgaard, N.; Galli, G.; Abe, A.; Taylor, E.W.; Wang, T. The role of nitric oxide in regulation of the cardiovascular system in reptiles. Comp. Biochem. Physiol. A Mol. Integr. Physiol 2005, 142, 205–214. [Google Scholar]
  52. Wang, J.; Dudley, D.; Wang, X.L. Haplotype-specific effects on endothelial no synthase promoter efficiency: Modifiable by cigarette smoking. Arteriosclerosis 2002, 22, e1–e4. [Google Scholar]
  53. Yoon, Y.; Song, J.; Hong, S.H.; Kim, J.Q. Plasma nitric oxide concentrations and nitric oxide synthase gene polymorphisms in coronary artery disease. Clin. Chem 2000, 46, 1626–1630. [Google Scholar]
  54. Lee, W.H.; Hwang, T.H.; Oh, G.T.; Kwon, S.U.; Choi, Y.H.; Park, J.E. Genetic factors associated with endothelial dysfunction affect the early onset of coronary artery disease in Korean males. Vasc. Med 2001, 6, 103–108. [Google Scholar]
  55. Angeline, T.; Isabel, W.; Tsongalis, G.J. Endothelial nitric oxide gene polymorphisms, nitric oxide production and coronary artery disease risk in a South Indian population. Exp. Mol. Pathol 2010, 89, 205–208. [Google Scholar]
  56. Syed, R.; Biyabani, M.U.; Prasad, S.; Deeba, F.; Jamil, K. Correlation and identification of variable number of tandem repeats of eNOS gene in coronary artery disease (CAD). Saudi J. Biol. Sci 2010, 17, 209–213. [Google Scholar]
  57. DerSimonian, R.; Laird, N. Meta-analysis in clinical trials. Control. Clin. Trials 1986, 7, 177–188. [Google Scholar]
Ijms 15 07987f1 1024
Figure 1. Flow diagram of study identification.
Figure 1. Flow diagram of study identification.
Ijms 15 07987f1
Ijms 15 07987f2 1024
Figure 2. Forest plot of CAD risk associated with the eNOS 4b/a polymorphism by source of control (homozygote comparison).
Figure 2. Forest plot of CAD risk associated with the eNOS 4b/a polymorphism by source of control (homozygote comparison).
Ijms 15 07987f2
Ijms 15 07987f3 1024
Figure 3. Begg’s funnel plot of publication bias test (homozygote comparison). (a) Before trim and fill method; and (b) After trim and fill method.
Figure 3. Begg’s funnel plot of publication bias test (homozygote comparison). (a) Before trim and fill method; and (b) After trim and fill method.
Ijms 15 07987f3
Table
Table 1. Study Characteristics of genotypes in coronary artery disease (CAD) cases and controls in the analysis of endothelial nitric oxide synthase (eNOS) 4b/a polymorphism.
Table 1. Study Characteristics of genotypes in coronary artery disease (CAD) cases and controls in the analysis of endothelial nitric oxide synthase (eNOS) 4b/a polymorphism.
AuthorYearCountryEthnicitySource of controlsEnd pointsSample sizeGenotype distribution
ControlCase
ControlCaseaaabbbaaabbb
Wang et al.1996AustraliaCaucasianPBCAD15354915010218122409
Hibi et al.1998JapanAsianPBAMI357226568284448174
Ichihara et al.1998JapanAsianHBMI5504557974469107339
Odawara et al.1998JapanAsianHBCHD1224201910301131
Hooper et al.1999AmericanAfricanPBMI1851101568102145244
Nakagami et al.1999JapanAsianHBCAD3440192411821
Park et al.2000KoreaAsianPBAMI20612114915652393
Fowkes et al.2000UKCaucasianPBCHD30013756423143796
Pulkkinen et al.2000FinlandCaucasianPBCHD11030852679996203
Sigusch et al.2000GermanyCaucasianHBCHD4136251111528712159454
Granath et al.2001AustraliaCaucasianPBCAD6205671415844811138418
Alvarez et al.2001SpainCaucasianPBCAD300170672222237131
Hwang et al.2002TaiwanAsianHBCAD7014901456132116
Gardemann et al.2002GermanyCaucasianPBMI52812651314437125306934
Cine et al.2002TurkeyotherPBMI306207255249955143
Park et al.2004KoreaAsianHBACS142164730105421139
Agema et al.2004NetherlandsCaucasianPBCAD46675287738112195545
Letonja et al.2004SloveniaCaucasianPBCAD10915163073641104
Fatini et al.2004ItalyCaucasianPBACS5374771413838524138315
Milutinovic et al.2005SloveniaCaucasianNMCAD18821510581201160144
Rao et al.2005AmericaCaucasia + AfricanHBCAD501441173264098
Matyar et al.2005TurkeyotherHBCAD1331331359754781
Salimi et al.2006IranotherNMCAD15814112912834197
Agirbasli et al.2006TurkeyotherHBCAD1001000217942175
Kim et al.2007KoreaAsianPBCAD211147040171235110
Rios et al.2007BrazilCaucasia + AfricanHBCAD267323129016518101204
Sampaio et al.2007BrazilotherHBAMI1031154326742982
Vasilakou et al.2008GreeceCaucasianPBCAD161209539117960140
Meluzin et al.2009Czech repCaucasianHBCAD893210266310103208
Kincl et al.2009Czech repCaucasianHBCAD22293996315035272632
Bae et al.2010KoreaAsianPBCAD196192035161242148
Gururajan et al.2010IndiaAsianNMACS10010641977123658
Jaramillo et al.2010ChileotherPBCAD1121121169531297
Jemaaa et al.2012TunisiaAfricanPBMI25031046118515105190
Da Costa Escobar Piccoli et al.2012BrazilotherPBACS10813263468143187
Kallel et al.2013TunisiaAfricanPBMI22530335816415101187
Narne et al.2013IndiaAsianHBCAD12116024277550105
Abbreviations: eNOS, endothelial nitric oxide synthase; HB, hospital-based; PB, population-based; NM, not mentioned; OR, odds ratios; CI, confidence intervals; CAD, coronary artery disease; CHD, coronary heart disease; MI, myocardial infarction; AMI, acute myocardial infarction; and ACS, acute coronary syndrome.
Table
Table 2. Pooled odds ratios (OR) and 95% confidence intervals (CI) of the association between eNOS 4b/a polymorphism and CAD.
Table 2. Pooled odds ratios (OR) and 95% confidence intervals (CI) of the association between eNOS 4b/a polymorphism and CAD.
Total and subgroupsStudiesHomozygote comparison (aa vs. bb)Heterozygote comparison (ab vs. bb)Dominant model (aa + ab vs. bb)Recessive model (ab + bb vs. aa)
OR (95% CI)pI2 (%)OR (95% CI)pI2 (%)OR (95% CI)pI2 (%)OR (95% CI)pI2 (%)
Total371.47 (1.16–1.87)0.08525.51.14 (1.02–1.27)<0.00156.71.18 (1.06–1.33)<0.00161.10.72 (0.58–0.89)0.21315.4
MI62.30 (1.17–4.51)0.02062.61.42 (1.07–1.89)0.00274.21.50 (1.09–2.07)<0.00180.70.56 (0.39–0.82)0.05454.1
Ethnicity
Caucasian161.03 (0.80–1.31)0.6210.01.04 (0.90–1.20)0.00653.31.04 (0.91–1.19)0.00753.00.98 (0.77–1.25)0.6790.0
Asian111.82 (1.03–3.20)0.31613.81.21 (0.96–1.54)0.02750.51.26 (0.99–1.61)0.01156.30.60 (0.36–0.99)0.4340.4
African52.93 (1.71–5.03)0.8210.01.46 (1.16–1.83)0.3539.41.58 (1.27–1.96)0.3706.50.41 (0.24–0.70)0.6840.0
Other72.65 (1.37–5.13)0.3697.81.17 (0.84–1.62)0.03356.41.29 (0.94–1.77)0.03356.30.39 (0.21–0.71)0.5110.0
Source of control
HB141.11 (0.78–1.56)0.5090.01.04 (0.88–1.23)0.07238.21.07 (0.89–1.27)0.02746.80.90 (0.64–1.26)0.6130.0
PB201.64 (1.18–2.27)0.07033.91.16 (1.00–1.35)<0.00161.81.21 (1.05–1.40)<0.00163.40.65 (0.48–0.89)0.11328.7
NM32.05 (0.66–6.32)0.11154.41.54 (0.80–2.98)0.01177.61.63 (0.80–3.30)0.00382.60.58 (0.24–1.40)0.23231.6
Case size
>50060.88 (0.62–1.24)0.6660.00.96 (0.74–1.25)<0.00178.70.97 (0.76–1.22)0.00175.91.14 (0.80–1.60)0.6420.0
<500311.75 (1.35–2.28)0.26213.21.20 (1.07–1.35)0.01140.71.26 (1.11–1.42)0.00248.00.61 (0.48–0.77)0.4530.8
Control size
>50041.21 (0.72–2.05)0.13845.61.07 (0.85–1.36)0.02468.31.09 (0.84–1.42)0.00775.10.84 (0.52–1.34)0.21433.1
<500331.56 (1.19–2.05)0.11323.91.15 (1.01–1.31)<0.00155.61.20 (1.06–1.36)<0.00159.00.68 (0.53–0.88)0.23314.8
Abbreviations: eNOS, endothelial nitric oxide synthase; OR, odds ratios; CI, confidence intervals; MI, myocardial infarction; HB, hospital-based; PB, population-based; and NM, not mentioned.

Share and Cite

MDPI and ACS Style

Yang, Y.; Du, K.; Liu, Z.; Lu, X. Endothelial Nitric Oxide Synthase (eNOS) 4b/a Gene Polymorphisms and Coronary Artery Disease: Evidence from a Meta-Analysis. Int. J. Mol. Sci. 2014, 15, 7987-8003. https://doi.org/10.3390/ijms15057987

AMA Style

Yang Y, Du K, Liu Z, Lu X. Endothelial Nitric Oxide Synthase (eNOS) 4b/a Gene Polymorphisms and Coronary Artery Disease: Evidence from a Meta-Analysis. International Journal of Molecular Sciences. 2014; 15(5):7987-8003. https://doi.org/10.3390/ijms15057987

Chicago/Turabian Style

Yang, Yujiao, Kang Du, Zhengxia Liu, and Xiang Lu. 2014. "Endothelial Nitric Oxide Synthase (eNOS) 4b/a Gene Polymorphisms and Coronary Artery Disease: Evidence from a Meta-Analysis" International Journal of Molecular Sciences 15, no. 5: 7987-8003. https://doi.org/10.3390/ijms15057987

APA Style

Yang, Y., Du, K., Liu, Z., & Lu, X. (2014). Endothelial Nitric Oxide Synthase (eNOS) 4b/a Gene Polymorphisms and Coronary Artery Disease: Evidence from a Meta-Analysis. International Journal of Molecular Sciences, 15(5), 7987-8003. https://doi.org/10.3390/ijms15057987

Article Metrics

Back to TopTop